Estimaciones de analistas de Wall Street para GT Biopharma, Inc. (GTBP): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 4 |
| Mantener | 1 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 5 |
| Calificación media (1-5) | 0.80 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-2.50 | ||
| 2026-08-14 | $-3.00 | $-2.00 | -50.0% |
| 2026-05-21 | $-0.11 | $-2.00 | +94.5% |
| 2026-03-02 | $-55.50 | $-5.50 | -909.1% |
| 2025-11-13 | $-0.83 | $-9.50 | +91.3% |
| 2025-08-13 | $-0.55 | $-17.00 | +96.8% |
| 2025-05-21 | $-0.33 | $-16.00 | +97.9% |
| 2025-03-25 | $-1.67 | $-38.75 | +95.7% |
Ratios de valoración
| Precio / Valor contable | 3.40 |
| EV / EBITDA | -0.48 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $1000 | $2000 | $7000 | $4000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$1000 | -$2000 | -$7000 | -$4000 | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $975000 | $1.1M | $9.1M | $1.7M | $485000 | $9.6M | $8.8M | $6.5M | $5.8M | $3.5M |
| Generales y Administrativos | $8.4M | $134.5M | $12.5M | $9.8M | $6.3M | $47.9M | $12.4M | $7.1M | $8.6M | $8.9M |
| Gastos Operativos | $9.4M | $135.6M | $21.6M | $11.5M | $6.8M | $57.5M | $21.3M | $13.6M | $14.4M | $12.4M |
| Beneficio Operativo | -$9.4M | -$135.6M | -$250.1M | -$11.5M | -$6.8M | -$57.5M | -$21.3M | -$13.6M | -$14.4M | -$12.4M |
| EBITDA | -$9.4M | -$135.6M | -$250.1M | -$36.5M | -$25.0M | -$57.5M | -$21.0M | $6.0M | -$13.2M | -$28.2M |
| Gastos por Intereses | $6.6M | $8.6M | $9.1M | $2.1M | $3.3M | $718000 | $8000 | $213000 | 0 | $127000 |
| Beneficio Antes de Impuestos | $9.8M | -$144.2M | -$259.2M | -$38.6M | -$28.3M | -$58.0M | -$20.9M | -$7.6M | -$13.2M | -$28.4M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | $9.8M | -$144.2M | -$259.2M | -$38.6M | -$28.3M | -$58.0M | -$20.9M | -$7.6M | -$13.2M | -$28.4M |
| BPA | $1530000.00 | $-3630.50 | $-2192.50 | $-285.50 | $-161.25 | $-51.50 | $-16.50 | $-141.00 | $-173.50 | $-156.25 |
| BPA Diluido | $1530000.00 | $-3630.50 | $-2192.50 | $-285.50 | $-161.25 | $-51.50 | $-16.50 | $-141.00 | $-173.50 | $-156.25 |
| Acciones en Circulación (Diluidas) | $6 | $39457 | $118200 | $135400 | $175400 | $1.1M | $1.3M | $53920 | $75880 | $220530 |
Precio
| Precio | $7.81 |
| Capitalización | $10M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ARTL · CARM · DRMA · LIPO · PBM · PTIX · REVB
Explorar sector: Healthcare · Biotechnology
Más secciones de GTBP: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones